{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:40:11Z","timestamp":1786718411675,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pathol Microbiol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijpm.ijpm_781_17","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T08:06:54Z","timestamp":1531469214000},"page":"371","source":"Crossref","is-referenced-by-count":4,"title":["Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms"],"prefix":"10.4103","volume":"61","author":[{"given":"Kanwaljeet","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Sazawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Chhikara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoranjan","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0377-4929.236630-1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0377-4929.236630-2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key-10.4103\/0377-4929.236630-3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0377-4929.236630-4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","article-title":"A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications","author":"Harrison","year":"1999","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.236630-5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.2004.00219.x","article-title":"The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia","author":"Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"},{"key":"key-10.4103\/0377-4929.236630-6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"key-10.4103\/0377-4929.236630-7","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and jak2 mutation status","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.236630-8","first-page":"372","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments","author":"De","year":"2008","journal-title":"Haematologica"},{"key":"key-10.4103\/0377-4929.236630-9","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.236630-10","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2V617F mutational status","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"key-10.4103\/0377-4929.236630-11","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","article-title":"Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera","author":"Marchetti","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.236630-12","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0377-4929.236630-13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0377-4929.236630-14","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.exphem.2007.08.011","article-title":"The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia","author":"Hsiao","year":"2007","journal-title":"Exp Hematol"},{"key":"key-10.4103\/0377-4929.236630-15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","article-title":"A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)","author":"Finazzi","year":"2004","journal-title":"Pathol Biol (Paris)"},{"key":"key-10.4103\/0377-4929.236630-16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.leu.2404666","article-title":"Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: A single institutional study in japan","author":"Ohyashiki","year":"2007","journal-title":"Leukemia"},{"key":"key-10.4103\/0377-4929.236630-17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"key-10.4103\/0377-4929.236630-18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0377-4929.236630-19","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"Mechanisms of diseases: The myeloproliferative disorders","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0377-4929.236630-20","first-page":"543","article-title":"Is polycythemia vera a serious disease in young adults?","author":"Perea","year":"2001","journal-title":"Haematologica"},{"key":"key-10.4103\/0377-4929.236630-21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and lu\/BCAM","author":"Wautier","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.236630-22","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1074\/jbc.M501376200","article-title":"Janus kinases affect thrombopoietin receptor cell surface localization and stability","author":"Royer","year":"2005","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0377-4929.236630-23","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1538-7836.2007.02626.x","article-title":"Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V6I7F status, clonality, and antiphospholipid antibodies","author":"Robertson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key-10.4103\/0377-4929.236630-24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-007-0386-3","article-title":"Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis","author":"Alvarez-Larran","year":"2008","journal-title":"Ann Hematol"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:34:52Z","timestamp":1786714492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_781_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"alternative-id":["236630"],"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_781_17","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}